{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-22-001463","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.947744+00:00","generated_at":"2026-06-21T19:35:39.162221+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vivani Medical reports Q3 net income $1.4M on merger gain; NPM-119 on track for IND early 2023","bullets":["Net income of $1.4M in Q3 2022 vs net loss of $3.5M in Q3 2021, driven by $6.9M bargain purchase gain from merger.","Cash and equivalents $51.7M as of Sep 30, 2022; estimated to fund operations into second half of 2024.","R&D expenses $3.9M (up 34% YoY); G&A $1.6M (up 167% YoY) due to higher headcount from merger.","NPM-119 GLP-1 implant IND filing and LIBERATE-1 Phase 2 start expected early 2023; top-line results anticipated late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-22-001463","json":"https://secwatch.observer/filing/0001753926-22-001463.json","markdown":"https://secwatch.observer/filing/0001753926-22-001463.md","text":"https://secwatch.observer/filing/0001753926-22-001463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/0001753926-22-001463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/g083264_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:35:39.162221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06a2e832dacb765039f0d218532007cf94ac152a","claim":"Vivani Medical, Inc. reported the third quarter ended September 30, 2022 results: net income $1.4 million.","evidence_excerpt":"Net income was $1.4 million in the third quarter of 2022, compared to a net loss of $3.5 million in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/0001753926-22-001463-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$1.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}